Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 162 | $110,093,809 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 16 Jan 2024 | Sale | 65,979 | 67.25 | 4,437,088 | D |
18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 18 Jan 2024 | Sale | 67,597 | 65.19 | 4,406,648 | D |
23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 21 Aug 2024 | Sale | 44,134 | 75.4026 | 3,327,818 | D |
09 Aug 2023 18:05 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 07 Aug 2023 | Sale | 55,300 | 58.79 | 3,251,087 | D |
16 Jun 2023 17:05 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 14 Jun 2023 | Sale | 44,035 | 64.37 | 2,834,533 | D |
04 Jan 2024 19:54 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 02 Jan 2024 | Sale | 37,427 | 70.41 | 2,635,235 | D |
23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 22 Aug 2024 | Sale | 35,011 | 74.5787 | 2,611,075 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 17 Feb 2023 | Sale | 52,279 | 49.81 | 2,604,017 | D |
19 Sep 2023 20:40 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 19 Sep 2023 | Sale | 44,413 | 54.17 | 2,405,852 | D |
28 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 28 Aug 2024 | Sale | 32,459 | 72.7414 | 2,361,113 | D |
14 Nov 2023 17:33 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 13 Nov 2023 | Sale | 41,067 | 54.01 | 2,218,029 | D |
16 Jun 2023 17:05 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 14 Jun 2023 | Sale | 34,227 | 63.35 | 2,168,280 | D |
30 Aug 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 29 Aug 2024 | Sale | 29,832 | 72.4428 | 2,161,114 | D |
23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 23 Aug 2024 | Sale | 28,680 | 74.4573 | 2,135,435 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 07 Mar 2024 | Sale | 31,958 | 66.38 | 2,121,372 | D |
30 Aug 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 30 Aug 2024 | Sale | 28,203 | 72.732 | 2,051,261 | D |
12 Jan 2024 18:02 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Jan 2024 | Sale | 30,360 | 67.1 | 2,037,156 | D |
18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 17 Jan 2024 | Sale | 30,633 | 66 | 2,021,778 | D |
15 Dec 2022 19:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 13 Dec 2022 | Sale | 33,083 | 55 | 1,819,565 | D |
28 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 27 Aug 2024 | Sale | 23,657 | 73.3341 | 1,734,865 | D |
28 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 26 Aug 2024 | Sale | 22,713 | 74.5929 | 1,694,229 | D |
04 Jan 2024 19:54 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 02 Jan 2024 | Sale | 22,645 | 70.8 | 1,603,266 | D |
19 Sep 2023 20:40 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 18 Sep 2023 | Sale | 28,119 | 53.96 | 1,517,301 | D |
13 Mar 2023 19:31 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 10 Mar 2023 | Sale | 34,965 | 43.28 | 1,513,285 | D |
23 Sep 2022 21:01 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Sep 2022 | Sale | 33,303 | 45.39 | 1,511,623 | D |
08 Nov 2023 17:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 06 Nov 2023 | Sale | 26,754 | 55.9817 | 1,497,734 | D |
19 Sep 2023 20:40 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 18 Sep 2023 | Sale | 27,468 | 53.55 | 1,470,911 | D |
02 Dec 2022 19:14 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 01 Dec 2022 | Sale | 27,204 | 53.94 | 1,467,384 | D |
23 Sep 2022 21:01 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Sep 2022 | Sale | 31,861 | 45.88 | 1,461,783 | D |
20 Aug 2024 18:03 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 16 Aug 2024 | Sale | 18,714 | 75.08 | 1,405,047 | D |
15 Dec 2023 17:01 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 13 Dec 2023 | Sale | 21,262 | 65 | 1,382,030 | D |
28 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 27 Aug 2024 | Sale | 16,856 | 73.9316 | 1,246,191 | D |
27 Feb 2024 19:57 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 26 Feb 2024 | Sale | 17,658 | 69.07 | 1,219,638 | D |
02 Dec 2022 19:14 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 01 Dec 2022 | Sale | 22,796 | 53.48 | 1,219,130 | D |
12 Jan 2024 18:02 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Jan 2024 | Sale | 18,154 | 66.31 | 1,203,792 | D |
05 Feb 2024 18:10 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 02 Feb 2024 | Sale | 17,450 | 67.42 | 1,176,479 | D |
18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 17 Jan 2024 | Sale | 17,451 | 66.66 | 1,163,284 | D |
05 Feb 2024 18:10 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 02 Feb 2024 | Sale | 16,435 | 66.7 | 1,096,214 | D |
22 Feb 2023 20:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 21 Feb 2023 | Sale | 22,895 | 46.54 | 1,065,533 | D |
27 Feb 2023 19:59 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 24 Feb 2023 | Sale | 22,590 | 47.03 | 1,062,408 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 14,541 | 64.8 | 942,257 | D |
27 Feb 2024 19:59 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 26 Feb 2024 | Sale | 12,462 | 70.11 | 873,711 | D |
13 Mar 2023 19:31 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 13 Mar 2023 | Sale | 19,153 | 45.06 | 863,034 | D |
08 Nov 2023 17:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 06 Nov 2023 | Sale | 15,639 | 55.0174 | 860,417 | D |
11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 07 Mar 2024 | Sale | 12,912 | 66.14 | 854,000 | D |
21 Jun 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 18 Jun 2024 | Sale | 11,109 | 76.07 | 845,062 | D |
28 Feb 2024 19:41 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 27 Feb 2024 | Sale | 10,349 | 73.14 | 756,926 | D |
05 Feb 2024 18:13 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 02 Feb 2024 | Sale | 11,146 | 66.37 | 739,760 | D |
05 Feb 2024 18:05 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 02 Feb 2024 | Sale | 10,998 | 66.61 | 732,577 | D |
28 Feb 2024 19:41 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 27 Feb 2024 | Sale | 9,651 | 72.71 | 701,724 | D |
21 Jun 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 18 Jun 2024 | Sale | 8,891 | 75.71 | 673,138 | D |
27 Feb 2024 19:59 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 26 Feb 2024 | Sale | 9,528 | 69.45 | 661,720 | D |
19 Apr 2023 18:00 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 17 Apr 2023 | Sale | 10,000 | 63 | 630,000 | D |
13 Mar 2023 19:34 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 10 Mar 2023 | Sale | 14,208 | 43.2 | 613,786 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 07 Mar 2024 | Sale | 8,754 | 66.93 | 585,905 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 07 Mar 2024 | Sale | 8,636 | 66.37 | 573,171 | D |
27 Feb 2024 19:57 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 26 Feb 2024 | Sale | 8,371 | 67.83 | 567,805 | D |
13 Mar 2023 19:32 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 10 Mar 2023 | Sale | 12,963 | 43.17 | 559,613 | D |
30 Mar 2023 17:08 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 28 Mar 2023 | Sale | 10,183 | 54.01 | 549,984 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 26 Feb 2024 | Sale | 7,215 | 69.54 | 501,731 | D |
14 Nov 2023 17:33 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 13 Nov 2023 | Sale | 8,933 | 53.37 | 476,754 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 6,867 | 69.38 | 476,432 | D |
05 Feb 2024 18:07 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 02 Feb 2024 | Sale | 6,904 | 67.49 | 465,951 | D |
30 Aug 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 30 Aug 2024 | Sale | 6,193 | 73.3232 | 454,091 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 07 Mar 2024 | Sale | 6,618 | 66.93 | 442,943 | D |
22 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 21 Feb 2023 | Sale | 9,296 | 46.56 | 432,822 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 07 Mar 2024 | Sale | 6,514 | 66.26 | 431,618 | D |
30 Aug 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 29 Aug 2024 | Sale | 5,772 | 73.2451 | 422,771 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Feb 2023 | Sale | 8,649 | 46.54 | 402,524 | D |
11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Mar 2024 | Sale | 6,107 | 65.82 | 401,963 | D |
18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 16 Jan 2024 | Sale | 5,882 | 67.76 | 398,564 | D |
27 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 24 Feb 2023 | Sale | 7,906 | 47.14 | 372,689 | D |
27 Feb 2023 20:01 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 24 Feb 2023 | Sale | 7,906 | 47.03 | 371,819 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 5,282 | 69.47 | 366,941 | D |
03 Mar 2023 19:03 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 01 Mar 2023 | Sale | 7,241 | 50.01 | 362,122 | D |
27 Feb 2023 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 24 Feb 2023 | Sale | 7,455 | 47.03 | 350,609 | D |
25 Jun 2024 18:04 | ITCI | Intra-Cellular Therapies Inc | RIGGS RORY B | Director | 24 Jun 2024 | Sale | 4,462 | 75.57 | 337,193 | D |
05 Feb 2024 18:07 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 02 Feb 2024 | Sale | 4,956 | 66.67 | 330,417 | D |
23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 22 Aug 2024 | Sale | 4,369 | 75.4697 | 329,727 | D |
23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 21 Aug 2024 | Sale | 4,297 | 76.2001 | 327,432 | D |
13 Mar 2023 19:36 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 13 Mar 2023 | Sale | 6,998 | 45.08 | 315,470 | D |
22 Feb 2023 20:04 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 21 Feb 2023 | Sale | 6,673 | 46.55 | 310,628 | D |
13 Mar 2023 19:34 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 13 Mar 2023 | Sale | 6,868 | 44.99 | 308,991 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 07 Mar 2024 | Sale | 4,496 | 66.95 | 301,007 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 4,475 | 66.47 | 297,453 | D |
30 Mar 2023 17:08 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 28 Mar 2023 | Sale | 5,421 | 54.86 | 297,396 | D |
13 Mar 2023 19:35 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 10 Mar 2023 | Sale | 6,750 | 43.5 | 293,625 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 4,453 | 65.28 | 290,692 | D |
13 Mar 2023 19:31 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 10 Mar 2023 | Sale | 6,805 | 42.51 | 289,281 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 26 Feb 2024 | Sale | 4,059 | 69.56 | 282,344 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 11 Mar 2024 | Sale | 4,303 | 65.11 | 280,168 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 4,128 | 65.9 | 272,035 | D |
08 Nov 2022 16:12 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 07 Nov 2022 | Sale | 5,000 | 52.4929 | 262,464 | D |
08 Nov 2022 16:12 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 07 Nov 2022 | Sale | 5,000 | 52.1117 | 260,558 | D |
05 Feb 2024 18:02 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 02 Feb 2024 | Sale | 3,847 | 67.49 | 259,634 | D |
21 Dec 2022 16:06 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 19 Dec 2022 | Sale | 5,000 | 50.82 | 254,100 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 07 Mar 2024 | Sale | 3,728 | 66.34 | 247,316 | D |
13 Mar 2023 19:32 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 13 Mar 2023 | Sale | 5,324 | 44.97 | 239,420 | D |
16 Jun 2023 17:05 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 14 Jun 2023 | Sale | 3,592 | 65.01 | 233,516 | D |
18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 16 Jan 2024 | Sale | 3,500 | 66.38 | 232,330 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)